—— The Phase 1b/2 study FUMANBA-1 demonstrates Equecabtagene Autoleucel led to deep and durable responses in patients with R/RMM —— The data shows the overall response rate（ORR）was 96.1%，the ORR reached 98.9% among the patients without prior CAR-T therapy ——Among the 103 patients, only…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.